J Ints Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from J ints bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In J Ints Bio Today - Breaking & Trending Today

J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

/PRNewswire/ J INTS BIO announced the results of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, at the 8th. ....

United States , Soult Ukpyolsi , South Korea , San Diego , American Cancer Research Society , Cancer Research Society , Annual Meeting , Dose Level , Partial Response , J Ints Bio , Medical Pharmaceuticals , Health Care Amp Hospitals , New Products Amp Services , Clinical Trials Amp Medical Discoveries ,

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

/PRNewswire/ J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI JIN-A02 were. ....

South Korea , Soult Ukpyolsi , Egfr Tkis Osimertinib , Dose Escalation , J Ints Bio , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries , Trade Show News ,

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI

/PRNewswire/ J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI JIN-A02 was presented at the 2023 IASLC. ....

South Korea , Soult Ukpyolsi , Lung Cancer , Non Small Cell Lung Cancer , Targeted Therapy , Dose Level One , J Ints Bio , Medical Pharmaceuticals , Health Care Amp Hospitals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries , Trade Show News ,

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Dosing of First Patient in the Global Multi-center Phase 1/2 Clinical Study began

/PRNewswire/ J INTS BIO announced the successful dosing of the first patient in its global multi-center Phase 1/2 clinical study of JIN-A02 on 31st July. ....

South Korea , Soult Ukpyolsi , Kyongsang Bukto , United States , Nanna Jo , Chungbuk National University Hospital , Asan Medical Center , Korea National Cancer Center , Seoul National University Hospital , Severance Hospital , National Cancer Center , Samsung Seoul Hospital , Vincent Hospital , J Ints Bio ,

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

/PRNewswire/ Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for. ....

United States , South Korea , Soult Ukpyolsi , Nanna Jo , Wook Je Cho , American Cancer Research Association , Prnewswire Yuhan Corporation , Yuhan Corporation , Tyrosine Kinase Inhibitor , J Ints Bio ,